AbbVie's Dividend Looks Unsustainable. The Cash Flow Says Otherwise.

AbbVie declared its quarterly dividend of $1.73 per share for the third time this year. It is not a surprise move — the board raised the rate from $1.64 to $1.73 at the start of 2026, and it has been paying that amount steadily since. Over the past 12 months, that adds up to $6.83 per share, or a 2.7% yield against the current stock price.

The headline is unremarkable. The numbers behind it are not.

If you look at AbbVie's official earnings payout ratio — the fraction of earnings paid out as dividends — it reads 323%. A payout ratio above 100% means a company is giving away more in dividends than it earns. Anything above 300% normally signals a cut is coming.

Except AbbVie's dividend has grown every year since the company spun off from Abbott in 2013, now 12 consecutive increases in a row. So what gives?

The earnings puzzle and the cash reality

The 323% payout ratio is calculated using GAAP earnings, which include large non-cash charges — amortization of acquired intellectual property, restructuring costs, and impairment write-downs. These reduce reported profit on paper but do not touch the cash sitting in AbbVie's bank account. Cash is what pays the dividend, not accounting profit.

The actual cash engine is much easier on the eye. AbbVie generated roughly $18.2 billion in free cash flow over the past 12 months. The annual dividend bill is about $12.2 billion — $1.73 per quarter multiplied by roughly 1.77 billion shares outstanding. That leaves a free cash flow coverage ratio of about 1.5x, meaning the business produces 50% more cash than the dividend requires.

When you look at adjusted earnings instead of GAAP — the measure management uses to guide investors — the coverage is even clearer. AbbVie's 2026 adjusted EPS guidance sits in the range of $14.08 to $14.28. Against an annual dividend of $6.92, the adjusted payout ratio is roughly 49%. That is solid territory.

The reason the two numbers diverge so far apart is that AbbVie has spent billions acquiring assets — most notably the $63 billion Allergan deal and subsequent investments. Those purchases create massive amortization charges on the income statement. The cash went out the door long ago. The amortization drags on for years.

What is actually producing the cash

Three years ago, AbbVie was judged by a single question: how bad would the Humira patent cliff be? Humira, once the world's best-selling drug, began losing U.S. exclusivity in 2023. In the first quarter of 2026, Humira revenue fell 38.6% year-over-year to $688 million. The cliff has arrived.

But the company that matters today is not the company that Humira built. Global immunology revenue — the core franchise — rose 16.4% to $7.29 billion in the first quarter of 2026. Two drugs are doing the heavy lifting:

Skyrizi, a treatment for psoriasis and Crohn's disease, generated $4.48 billion in the quarter, up 30.9%. Rinvoq, an oral pill for rheumatoid arthritis and other autoimmune conditions, brought in $2.12 billion, up 23.3%. Together, they produced over $6.6 billion in a single quarter from drugs that are still relatively early in their commercial curves. Both have approved indications that are expanding and new regulatory submissions in development.

Neuroscience — with products like Vraylar, Ubrelvy, Qulipta, and Botox — added another $2.88 billion, up 26%. The aesthetics business, including Botox Cosmetic, grew 7.6% to $1.19 billion. AbbVie reported 12% overall revenue growth in the first quarter, and management raised its full-year EPS guidance despite absorbing acquisition-related charges.

In short, the Humira decline is real, but the replacement engine is already running and accelerating. The dividend is not being propped up. It is being outgrown.

The risks the yield alone hides

A 2.7% yield does not demand heroic faith. But it does deserve scrutiny. The payout is covered today. The question for an income investor is whether it will be covered in three years — when Skyrizi and Rinvoq face their own patent timelines, when the debt load has been serviced through multiple rate cycles, and when the stock has traded to its current valuation.

Debt is the first structural concern. AbbVie carries $141 billion in total debt, a figure driven by a series of major acquisitions over the years. With $6.6 billion in cash on hand, net debt sits around $64 billion. That is manageable against $18+ billion in annual free cash flow, but it is not light. The company has also been an aggressive buyer of its own shares, and that discipline has pushed total equity to negative territory — roughly -$5.9 billion. You cannot calculate a meaningful price-to-book ratio when book value is underwater. The negative equity is not distress; it is the mathematical result of years of share buybacks exceeding retained earnings. Still, it means the balance sheet offers less cushion than it would if the company had kept that cash.

Valuation is the second concern. AbbVie's market capitalization of $451 billion reflects a stock that has risen 23.7% over the past four months and 11.6% year-to-date. It trades at roughly 71 times trailing GAAP earnings — which, again, includes those amortization charges that depress the denominator. Even on an adjusted forward basis, the multiple is around 18x, which is not cheap for a drug company. The market has already priced in the Skyrizi-Rinvoq growth story. You are not buying AbbVie at a discount. You are buying it at the price of a company that has proven its transition works.

That matters for the dividend investor because it means the margin for error is thinner. If Skyrizi growth decelerates from 30% to 15%, or if Rinvoq runs into competitive pressure, earnings guidance gets revised, the stock drops, and the yield rises — but on a weaker foundation. The dividend would likely survive because of the cash cushion, but the dividend growth streak would come under pressure.

Where the stock fits in an income portfolio

AbbVie is not a yield play. At 2.7%, it does not compete with Pfizer at 6.2% or Bristol-Myers Squibb at 3.9%. It does not have the dividend aristocrat pedigree of Johnson & Johnson, which has raised its payout for more than six decades. AbbVie has 12. For a company that only became independent in 2013, that is impressive. But it is not a multi-decade record.

What AbbVie offers is dividend growth backed by a cash flow engine that is currently compounding. The post-Humira transition — which investors feared for years — appears to have worked better than the consensus expected. Skyrizi and Rinvoq are growing fast enough to not just replace Humira but to push the entire company higher. Free cash flow is strong. Coverage is comfortable.

For an income portfolio, AbbVie serves as a growth-dividend holding: moderate current yield with meaningful reinvestment upside if the immunology compounds continue to expand. It belongs alongside established payers in a diversified setup, not as the sole anchor of a retirement plan. The stock deserves its place because the cash engine is real, and the payout is earned.

The condition that changes the story is straightforward. Watch immunology growth rates. If Skyrizi and Rinvoq continue in the 20-30% range, the dividend keeps growing and the income position stays strong. If those rates collapse below single digits, or if new competitors erode market share faster than expected, the coverage margin narrows and the stock's valuation premium becomes harder to defend. Until then, the dividend machine is running, and the lower the price on a temporary dip, the more future income a patient investor can buy for the same dollars.